TTR and cardiac amyloidosis: ATTRUBY (acoramidis) is a transthyretin stabilizer approved by the FDA on 22 November 2024 for treating wild-type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and hospitalization risks [27].